ANI Pharmaceuticals appeared confident about its Cortrophin gel launch and integration of Novitium Pharma as it rounded up its Q1 results, but net losses have dampened the company’s share value.

Generic lenalidomide competitors to BMS’ Revlimid brand have brought the cost of the cancer drug down by as much as 60% in Germany just a couple of months after launch, according to local generics association Pro Generika. However, the industry body has warned, price pressure must not grow so pronounced that the generics market becomes unsustainable.

Sun Pharma has scooped a first ANDA approval for a rival to Takeda’s mesalamine-containing brand Pentasa, with Viatris making clear recently that it was eyeing a first-time generic launch for the gastrointestinal drug.

Japan’s Nippon Chemiphar and the International Finance Corporation have announced an alliance that will see the pair collaborate to boost local production of generics in Asia, the Middle East and Africa, as part of efforts to reduce reliance on imports.

Canadian provinces must consider the impact of inflation on generic drugs during the next round of off-patent price setting, says a study from Aviseo and the Canadian Generic Pharmaceutical Association.

Amneal highlighted the benefits of a broad spread of generics and an increased shift towards complex products with high barriers to entry, as it reported generics sales growth in Q1 despite a tough operating environment for US generics.

Perrigo is set to welcome a new chief financial officer and corporate security head as it rounds up a fairly successful first quarter.

Sandoz has introduced the first generic version of Roche’s landmark treatment for idiopathic pulmonary fibrosis, Esbriet (pirfenidone), after downing the originator’s attempts to stymie its launch.

Multiple different generics saw triple-digit-percentage price rises that led UK averages to as much as quadruple in April 2022, according to the latest figures from WaveData. Solifenacin and ibandronic acid led the month’s steepest increases.